Welcome to Shanghai Probechem Biochemicals Co Ltd !Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : STX-478
CAS No.: 2883540-92-7
Catalog No.: PC-21139Not For Human Use, Lab Use Only.
STX-478 (STX478) is a potent, mutant-selective, allosteric PI3Kα inhibitor with IC50 of 9.4 nM (PI3Kα H1047R), 14-fold selectivity over WT PI3Kα (IC50=131 nM).
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 2 mg | $398 | In stock | |
| 5 mg | $598 | In stock | |
| 10 mg | Get quote | ||
| 25 mg | Get quote | ||
| 100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
STX-478 (STX478) is a potent, mutant-selective, allosteric PI3Kα inhibitor with IC50 of 9.4 nM (PI3Kα H1047R), 14-fold selectivity over WT PI3Kα (IC50=131 nM).
STX-478 is less potent against E542K (IC50=113 nM) and E545K (IC50=71 nM) helical domain mutants, but not alpelisib (Cat# PC-20590).
STX-478 also demonstrates exquisite kinome-wide selectivity against a panel 373 kinases representing approximately 70% of the human kinome at 10 uM, including PI3Kβ, PI3Kδ, and PI3Kγ isoforms, with only one exception of AurB kinase (IC50=1.6 µM).
STX-478 selectively inhibits the proliferation of cell lines with kinase-domain and helical-domain mutations compared with cells expressing WT PI3Kα.
STX-478 selectively targets PI3Kα activity and cell viability in PI3Kα mutant cells.
STX-478 (100 mg/kg QD) exhibits robust anti-tumor efficacy in PI3Kα-mutant tumors without metabolic dysregulation in mice.
STX-478 is efficacious across a panel of PI3Kα-mutant CDX and PDX 17 tumors, without evidence of insulin resistance.
| M.Wt | 401.30 | |
| Formula | C16H12F5N5O2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
(R)-1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea |
|
1. Buckbinder L, et al. Cancer Discov. 2023 Aug 25:CD-23-0396.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
